Choosing the optimal management strategy for antiplatelet and anticoagulation medications at the time of cardiac device implantation can be challenging. Simply withholding or reversing these medications puts patients at risk of subsequent thromboembolic events. Equally, continuing these medications may unnecessarily increase the risk of bleeding complications. This article summarizes recent findings and provides compelling evidence challenging current recommendations outlined by various professional organizations.
|Original language||English (US)|
|Number of pages||7|
|State||Published - Feb 16 2011|
- Implantable cardioverter-defibrillator
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine